Source comparison
PT-141 Gene Expression Comparison
Onset Latency 30–45 min (gene transcription lag) 15–30 min (enzyme inhibition) 3–7 days (receptor density changes) PT-141's delayed onset reflects transcriptional mechanism—not a weakness but evidence of central action Duration of Effect 12–24 hours (protein h
This comparison does not assign a generated winner or score.
- Onset Latency
- 30–45 min (gene transcription lag)
- 15–30 min (enzyme inhibition)
- 3–7 days (receptor density changes)
- PT-141's delayed onset reflects transcriptional mechanism—not a weakness but evidence of central action
- Duration of Effect
- 12–24 hours (protein half-life)
- 4–6 hours (enzyme recovery)
- Continuous during treatment
- Gene expression changes outlast peptide plasma half-life by 4–8×
- Site of Action
- Hypothalamic MC4R → CREB → gene transcription
- Peripheral corpus cavernosum PDE5 enzyme
- Androgen receptor activation in multiple tissues
- Only PT-141 initiates arousal centrally through the CNS—others work peripherally or systemically
- Genes Upregulated
- c-Fos, Arc, oxytocin, NOS, dopamine D2 receptor
- None (enzyme inhibitor, not transcriptional modulator)
- Androgen response elements (hundreds of genes)
- Immediate early gene activation is the signature of PT-141—detectable via in situ hybridization in animal models
- Efficacy in Women
- 25–40% response rate in HSDD trials
- Minimal (no central arousal component)
- Variable (depends on androgen sensitivity)
- PT-141 is the only FDA-approved peptide for female sexual dysfunction—because it addresses arousal, not perfusion
- Bottom Line
- First-line for arousal disorders without vascular component
- First-line for erectile dysfunction with intact libido
- Indicated only when hypogonadism documented
- PT-141 fills a gap unaddressed by vasodilators or hormones—central arousal pathway modulation